Quinoline Derivatives as NK-3 Antagonists
AssigneesGlaxoSmithKline S.P.A. & Laboratoire, GlaxoSmithKline LLC
InventorsCarlo Farina, Stefania Gagliardi, Giuseppe Giardina, Mario Grugni, Marisa Martinelli, Guy Marguerite Nadler
Life of this patent
Estimating the term…
Abstract
Certain compounds of formula (I) below or a pharmaceutically acceptable salt or hydrate thereof: a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds and composition in medicine.
Claims39
A compound of formula (I) below or a pharmaceutically acceptable salt or hydrate thereof:
- wherein:
- R1 is H or alkyl;
- R2 is aryl or cycloalkyl or heteroaryl, optionally substituted one or more times by alkyl, OH or alkoxy;
- R3 is H or alkyl or cycloalkyl or cycloalkylalkyl, optionally substituted one or more times by hydroxy or by one or more fluorines;
- R4 is H, or —R8R9 where R8 is optionally substituted one or more times by R′3, or R19;
- R8 is alkyl or alkenyl;
- R9 is S(O2)R10, S(O2)OR10, ONO, C(O)OR10, C(O)NR′1R′2, or CN;
- R10 is H, alkyl, aryl or cycloalkyl;
- R11 and R12 are independently selected from H and alkyl;
- R13 is R14 or —R′4R′5;
- R14 is alkyl, aryl, cycloalkyl, arylalkyl, or a five-, six-, seven- or eight-membered heterocyclic ring comprising one or more heteroatoms selected from N, O and S;
- R15 is alkyl or —R′6COOR′7;
- R16 is a single bond or alkyl;
- R17 is H or alkyl;
- R18 is H or up to three oxo substituents;
- R19 is R20 or —R2OR21;
- R20 is alkyl, alkenyl or a single bond;
- R21 is OH, aryl, cycloalkyl or a saturated heterocyclic ring comprising one or more heteroatoms selected from N, O and S;
- R5 is a alkyl, cycloalkyl, cycloalkylalkyl, aryl, or single or fused ring aromatic heterocyclic group, which group may be substituted one or more times by halo, hydroxy, alkyl or alkyl substituted one or more times by halo or hydroxy;
- R6 represents H or up to three substituents independently selected from the list consisting of:
- alkyl, alkenyl, aryl, alkoxy or a hydroxylated derivative thereof, hydroxy, halogen, nitro, cyano, carboxy, alkylcarboxy, alkylcarboxyalkyl, haloalkyl such as trifluoromethyl, amino or mono- or di-alkylamino;
- or R6 represents a bridging moiety which is arranged to bridge two adjacent ring atoms, which bridging moiety comprises alkyl or dioxyalkylene;
- R7 is H or halo;
- a is 1-6;
- and
- any of R2, R5, R8, R10, R11, R12, R14, R16, R17 and R21 may optionally be substituted one or more times by halo, hydroxy, amino, cyano, nitro, carboxy or oxo;
- subject to the proviso that said compound is not a compound wherein R7 represents H, R5 represents unsubstituted phenyl, R18 is H, and R1, R2, R3 and R4 are one of the following combinations:
- a
- R4
- R6
- 1
- H
- 1
- H
- H
- 1
- H
- H
- 1
- H
- 2
- H
- 3
- H
- 4
- H
- 3
- H
- 2
- H
- 2
- H
- 3
- OMe
- 1
- H
- 1
- H
- 1
- H
- 1
- H
- 1
- H
- 1
- H
- 1
- Et
- H
- 1
- Me
- H
- 1
- H
- 2
- Me
- H
- 1
- Et
- H
- 1
- H
- 3
- OH
(canceled)
A compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the treatment or prophylaxis of the Primary and Secondary Conditions.
(canceled)
A method for the treatment and/or prophylaxis of the Primary and Secondary Conditions in mammals, particularly humans, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective, non-toxic pharmaceutically acceptable amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
Dependencies are inferred from the claim text.